GlassScriptPhysician profile
Glen P Morehead
NPI 1720169386
$6,564.48
in general payments reported to CMS, 2019-2025
46 companies · $2,138 in 2025
The $2,138 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $75.74 · 2021: $529 · 2022: $386 · 2023: $927 · 2024: $1,320 · 2025: $2,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,200 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,200.21 |
| Education | $185.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $908.09 | 2019-2025 | Enhertu, Imfinzi, Datroway |
| Janssen Biotech, INC. | $614.91 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Eisai INC. | $388.53 | 2022-2024 | |
| Amgen INC. | $357.51 | 2019-2025 | Imdelltra (Amg757) |
| Genzyme Corporation | $311.73 | 2019-2022 | |
| Astellas Pharma US INC | $297.38 | 2019-2025 | Vyloy, Xtandi |
| Regeneron Healthcare Solutions, INC. | $280.06 | 2024-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $229.53 | 2019-2022 | |
| Daiichi Sankyo INC. | $221.47 | 2019-2025 | Datroway |
| Abbvie INC. | $185.27 | 2019-2025 | |
| Incyte Corporation | $179.61 | 2019-2023 | Jakafi |
| Glaxosmithkline, LLC. | $168.69 | 2025 | Jemperli, Zejula |
| Menarini Silicon Biosystems, INC. | $168.08 | 2023 | Cellsearch |
| Beone Medicines USA, INC. | $158.67 | 2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $148.42 | 2019-2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $142.26 | 2021-2025 | Xpovio |
| Array Biopharma INC | $139.36 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Novocure INC. | $131.93 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Celgene Corporation | $124.83 | 2019-2025 | Opdualag, Breyanzi |
| Emd Serono, INC. | $120.65 | 2023 | Bavencio |
| Rigel Pharmaceuticals, INC. | $113.48 | 2022-2024 | Tavalisse, Rezlidhia |
| Novartis Pharmaceuticals Corporation | $93.48 | 2019-2024 | |
| Springworks Therapeutics, INC. | $91.26 | 2024-2025 | Ogsiveo |
| Sobi, INC | $85.56 | 2022-2023 | |
| Lilly USA, LLC | $82.28 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Sanofi-Aventis U.S. LLC | $79.75 | 2023 | |
| Pharmaessentia USA Corporation | $72.45 | 2023-2025 | Besremi |
| Beigene USA, INC. | $69.90 | 2024-2025 | Brukinsa, Tevimbra |
| Deciphera Pharmaceuticals INC. | $60.72 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Coherus Oncology, INC. | $49.40 | 2020-2024 | |
| Ge Healthcare | $48.38 | 2025 | |
| Kyowa Kirin, INC. | $42.13 | 2023 | Poteligeo |
| Pfizer INC. | $41.33 | 2021-2024 | |
| Blueprint Medicines Corporation | $40.66 | 2022-2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $39.66 | 2025 | Fruzaqla |
| Intuitive Surgical, INC. | $34.56 | 2024 | |
| Voximetry, INC. | $33.68 | 2024 | Voximetry Torch |
| Taiho Oncology, INC. | $32.92 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $26.26 | 2025 | Onivyde |
| Aveo Pharmaceuticals, INC. | $23.94 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.49 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $23.48 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.86 | 2019 | |
| Gilead Sciences, INC. | $22.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.70 | 2022 | |
| Agios Pharmaceuticals, INC. | $16.53 | 2024 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Morehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.